A little less than half of atherosclerotic cardiovascular disease (ASCVD) patients are treated for blood cholesterol according to 2013 clinical guidelines, with around half missing out on a statin prescription the guidelines would have recommended, according to a study published in the American Journal of Cardiology.

Stress disorders like PTSD and adjustment disorder were linked to adverse cardiovascular outcomes in a recent BMJ study, Reuters reports, with the greatest CV risk posed in the months directly after a patient is diagnosed with such a condition.

MicroRNAs could be key to treating heart failure, according to a study out of Boston Children’s Hospital and Zhejiang University School of Medicine in China.

Antibiotic use—particularly regimens that last for two months or more—was linked to an increased risk of CVD in a recent study of nearly 36,500 older women.

Eating a late dinner and skipping breakfast could raise heart patients’ risk of a repeat MI or death by up to fivefold, according to research published in the European Journal of Preventive Cardiology April 17.

The 71-year-old Framingham Heart Study has received $38 million from the National Heart, Lung, and Blood Institute to fund a new six-year study into the biology of aging.

The FDA has granted a breakthrough therapy designation to a novel reversal agent for ticagrelor called PB2452, PhaseBio Pharmaceuticals announced April 8.

Nursing home residents who were prescribed three or four preventive medications after myocardial infarction (MI) were 26% less likely to die within 90 days than those prescribed only one drug, researchers reported April 9 in Circulation: Cardiovascular Quality and Outcomes.